| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $137,850 | 2 | 8 |
Sells | $2,271,994 | 23 | 92 |
| Firestone Karen | director | 1 | $100,845 | 0 | $0 | $100,845 |
| Zeiher Bernhardt G | director | 1 | $37,005 | 0 | $0 | $37,005 |
| FRATES JAMES M | Chief Financial Officer | 0 | $0 | 3 | $229,410 | $-229,410 |
| Bedrosian Camille L | Chief Medical Officer | 0 | $0 | 3 | $313,019 | $-313,019 |
| Mazzariello Gina | Chief Legal Officer | 0 | $0 | 7 | $437,778 | $-437,778 |
| Cohen Joshua B | Co-Chief Executive Officer | 0 | $0 | 5 | $645,204 | $-645,204 |
| Klee Justin B. | Co-Chief Executive Officer | 0 | $0 | 5 | $646,583 | $-646,583 |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Amylyx Pharmaceuticals, Inc. have bought $137,850 and sold $2.27M worth of Amylyx Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Amylyx Pharmaceuticals, Inc. have bought $12.55M and sold $9.99M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Firestone Karen (director) — $100,845. Zeiher Bernhardt G (director) — $37,005.
The last purchase of 8,100 shares for transaction amount of $100,845 was made by Firestone Karen (director) on 2025‑12‑23.
| 2026-01-06 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 7,715 0.009% | $11.09 | $85,596 | +9.50% | |
| 2026-01-06 | Sale | Klee Justin B. | Co-Chief Executive Officer | 7,715 0.009% | $11.09 | $85,589 | +9.50% | |
| 2026-01-06 | Sale | FRATES JAMES M | Chief Financial Officer | 3,326 0.0039% | $11.11 | $36,954 | +9.50% | |
| 2025-12-23 | Firestone Karen | director | 8,100 0.0097% | $12.45 | $100,845 | -1.58% | ||
| 2025-12-01 | Sale | Bedrosian Camille L | Chief Medical Officer | 6,580 0.008% | $14.35 | $94,418 | -13.48% | |
| 2025-09-30 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 29,933 0.0354% | $14.35 | $429,469 | -0.74% | |
| 2025-09-30 | Sale | Klee Justin B. | Co-Chief Executive Officer | 29,975 0.0356% | $14.38 | $430,952 | -0.74% | |
| 2025-09-30 | Sale | FRATES JAMES M | Chief Financial Officer | 10,558 0.0128% | $14.65 | $154,650 | -0.74% | |
| 2025-09-30 | Sale | Bedrosian Camille L | Chief Medical Officer | 12,039 0.0145% | $14.58 | $175,518 | -0.74% | |
| 2025-09-30 | Sale | Mazzariello Gina | Chief Legal Officer | 8,828 0.0106% | $14.58 | $128,669 | -0.74% | |
| 2025-08-13 | Sale | Mazzariello Gina | Chief Legal Officer | 15,000 0.0169% | $8.34 | $125,046 | +58.61% | |
| 2025-08-12 | Sale | Mazzariello Gina | Chief Legal Officer | 15,000 0.0174% | $8.07 | $121,103 | +59.76% | |
| 2025-03-31 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 21,490 0.0237% | $3.47 | $74,482 | +158.76% | |
| 2025-03-31 | Sale | Klee Justin B. | Co-Chief Executive Officer | 21,490 0.0237% | $3.46 | $74,454 | +158.76% | |
| 2025-03-31 | Sale | FRATES JAMES M | Chief Financial Officer | 10,896 0.0121% | $3.47 | $37,806 | +158.76% | |
| 2025-03-31 | Sale | Bedrosian Camille L | Chief Medical Officer | 12,425 0.0137% | $3.47 | $43,082 | +158.76% | |
| 2025-03-31 | Sale | Mazzariello Gina | Chief Legal Officer | 9,192 0.0102% | $3.48 | $31,954 | +158.76% | |
| 2025-03-20 | Zeiher Bernhardt G | director | 10,000 0.0112% | $3.70 | $37,005 | +125.74% | ||
| 2025-03-03 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 4,595 0.0056% | $3.17 | $14,549 | +176.00% | |
| 2025-03-03 | Sale | Klee Justin B. | Co-Chief Executive Officer | 4,595 0.0056% | $3.15 | $14,483 | +176.00% |
| Klee Justin B. | Co-Chief Executive Officer | 3317586 3.9911% | $47.44M | 0 | 11 | |
| Cohen Joshua B | Co-Chief Executive Officer | 3317632 3.9911% | $47.44M | 0 | 11 | |
| FRATES JAMES M | Chief Financial Officer | 177104 0.2131% | $2.53M | 1 | 8 | +91.57% |
| Bedrosian Camille L | Chief Medical Officer | 175756 0.2114% | $2.51M | 0 | 5 | |
| Mazzariello Gina | Chief Legal Officer | 148141 0.1782% | $2.12M | 0 | 13 | |
| Firestone Karen | director | 63100 0.0759% | $902,330.00 | 4 | 0 | +109.32% |
| Zeiher Bernhardt G | director | 10000 0.012% | $143,000.00 | 1 | 0 | |
| Morningside Venture Investments Ltd | 10 percent owner | 6997302 8.4178% | $100.06M | 1 | 10 | +23.76% |
| ALS Invest 1 B.V. | 5937577 7.1429% | $84.91M | 0 | 1 | ||
| VIKING GLOBAL INVESTORS LP | 2300000 2.7669% | $32.89M | 1 | 0 | +23.76% | |
| MILNE GEORGE M JR | director | 858571 1.0329% | $12.28M | 2 | 1 | +73.62% |
| Olinger Margaret | Chief Commercial Officer | 214355 0.2579% | $3.07M | 1 | 1 | +36.36% |
| Yeramian Patrick D | Chief Medical Officer | 205605 0.2473% | $2.94M | 0 | 5 | |
| Cheng Isaac | director | 6578 0.0079% | $94,065.40 | 1 | 0 | +36.36% |
| Quimi Daphne | director | 5000 0.006% | $71,500.00 | 2 | 0 | +89.06% |
| FONTEYNE PAUL R. | director | 3947 0.0047% | $56,442.10 | 1 | 0 | +36.36% |
$8,217,280 | 112 | 46.33% | $1.3B | |
$607,159,124 | 92 | 3.55% | $1.32B | |
$14,874,415 | 78 | 37.43% | $1.18B | |
$61,783,526 | 37 | 18.57% | $1.25B | |
$530,111,731 | 35 | 8.69% | $1.25B | |
$31,271,604 | 28 | 28.69% | $1.11B | |
$150,196,329 | 28 | -8.09% | $1.23B | |
$121,322,364 | 24 | -6.74% | $1.25B | |
$135,656,796 | 20 | 30.66% | $1.26B | |
$49,930,821 | 19 | 34.14% | $1.1B | |
$21,945,105 | 15 | -26.51% | $1.09B | |
$48,220,484 | 14 | 2.13% | $1.05B | |
Amylyx Pharmaceuticals, Inc. (AMLX) | $49,967,154 | 11 | 62.08% | $1.19B |
$5,794,001 | 10 | 23.26% | $1.08B | |
$117,959,652 | 9 | -12.47% | $1.19B | |
$18,704,399 | 5 | -20.93% | $1.22B | |
$3,200,000 | 5 | -11.36% | $1.27B | |
$19,420,853 | 5 | 4.35% | $1.18B | |
$45,070 | 4 | 10.31% | $1.13B |
| Increased Positions | 99 | +63.06% | 43M | +52.45% |
| Decreased Positions | 69 | -43.95% | 15M | -18.22% |
| New Positions | 53 | New | 23M | New |
| Sold Out Positions | 19 | Sold Out | 2M | Sold Out |
| Total Postitions | 187 | +19.11% | 110M | +34.23% |
| Fmr Llc | $129,951.00 | 10.35% | 11.38M | +8M | +273.33% | 2025-09-30 |
| Perceptive Advisors Llc | $102,236.00 | 8.14% | 8.95M | +1M | +13.29% | 2025-09-30 |
| Blackrock, Inc. | $81,547.00 | 6.49% | 7.14M | +2M | +29.59% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $77,848.00 | 6.2% | 6.82M | -2M | -22.54% | 2025-09-30 |
| Tcg Crossover Management, Llc | $71,304.00 | 5.68% | 6.24M | +300,000 | +5.05% | 2025-09-30 |
| Vanguard Group Inc | $60,226.00 | 4.79% | 5.27M | +775,722 | +17.25% | 2025-09-30 |
| Saturn V Capital Management Lp | $52,588.00 | 4.19% | 4.6M | +1M | +41.23% | 2025-09-30 |
| Commodore Capital Lp | $46,542.00 | 3.71% | 4.08M | +4M | New | 2025-09-30 |
| First Light Asset Management, Llc | $38,324.00 | 3.05% | 3.36M | +3M | New | 2025-09-30 |
| Point72 Asset Management, L.P. | $31,863.00 | 2.54% | 2.79M | -2M | -38.49% | 2025-09-30 |